JPMorgan Chase & Co. Reiterates “Neutral” Rating for Thoratec (THOR)
Thoratec (NASDAQ:THOR)‘s stock had its “neutral” rating reiterated by investment analysts at JPMorgan Chase & Co. in a note issued to investors on Thursday. They currently have a $35.00 price objective on the stock, up from their previous price objective of $31.00. JPMorgan Chase & Co.’s price target would indicate a potential upside of 1.30% from the company’s current price.
A number of other analysts have also recently weighed in on THOR. Analysts at Canaccord Genuity raised their price target on shares of Thoratec from $37.00 to $39.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at TheStreet downgraded shares of Thoratec from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Thoratec in a research note on Wednesday, May 21st. They now have a $33.00 price target on the stock. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Thoratec currently has an average rating of “Buy” and an average target price of $42.27.
Thoratec (NASDAQ:THOR) traded up 1.48% on Thursday, hitting $35.05. The stock had a trading volume of 242,978 shares. Thoratec has a 52 week low of $30.01 and a 52 week high of $43.58. The stock has a 50-day moving average of $33.34 and a 200-day moving average of $34.70. The company has a market cap of $1.991 billion and a P/E ratio of 27.20.
Thoratec (NASDAQ:THOR) last released its earnings data on Tuesday, May 6th. The company reported $0.41 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.39 by $0.02. The company had revenue of $125.70 million for the quarter, compared to the consensus estimate of $122.56 million. During the same quarter in the previous year, the company posted $0.41 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. Analysts expect that Thoratec will post $1.77 EPS for the current fiscal year.
Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.